Clinical Trial: Safety, Tolerability and Pharmacokinetics of KAI-4169 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: A Double-Blind, Randomized, Placebo-Controlled, Two-Period Crossover Study to Assess the Safety and Tolerability of Single Ascending Doses of KAI-4169 in Hemodialysis Subjects With Same as current
Current Secondary Outcome:
- Assess the effect of KAI-4169 on iPTH and serum calcium [ Time Frame: 3 days ]
- Pharmacokinetics of rising single doses of KAI-4169 by IV injection in hemodialysis subjects with secondary hyperparathyroidism [ Time Frame: 3 days ]
Original Secondary Outcome: Same as current
Information By: KAI Pharmaceuticals
Dates:
Date Received: May 28, 2010
Date Started: August 2010
Date Completion:
Last Updated: August 31, 2011
Last Verified: August 2011